Sodium–glucose cotransporter 2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, have emerged as effective therapeutic agents for managing obesity-related CKD, particularly in patients with type 2 diabetes. Here, SLC5A2 is linked to Obesity.